Dublin, Feb. 10, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/4s4ldq/in_vitro_cancer) has announced the addition of the "In Vitro Cancer Diagnostic Markets Global Market Size, Strategies and Forecasts 2016 to 2020 " report to their offering.
The Diagnostic, Monitoring and Screening Test opportunities are explored.
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.
Use independent research that makes you the expert. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it.
Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.
The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers. What is the size of the huge screening opportunity?
Key Topics Covered:
1. Introduction and Market Definition
2. Market Overview
2.1 Market Participants
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.3.1 Cell Separation and Viewing Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Conditions Identified with Biopsies
2.2.1 Cancer
2.2.2 Precancerous conditions
2.2.3 Inflammatory condiditons
2.3 Biopsy Sites
2.4 Analysis of Biopsied Material
2.5 Evidence of Cancer - Liquid Biopsy Technology
2.5.1 Liquid Biopsy Technology Overview
2.5.2 Circulating Tumor Cells
2.5.2.1 Types of CTCs
2.5.2.2 CellSearch Detection Method
2.5.2.3 Epic Sciences Detection Method
2.5.2.4 Maintrac Detection Method
2.5.2.5 Other Methods
2.5.3 Circulating Tumor DNA
2.5.4 Exosomes and Micro Vesicles
2.6 Changing the Cancer Treatment Protocol
2.6.1 Issues and Limitations to Liquid Biopsy Adoption
2.6.2 The Cancer Screening Market Opportunity
2.6.2.1 GRAIL - Exploiting the Screening Opportunity
2.6.3 Cancer Management
2.6.3.1 Risk Assessment Role In Cancer Management
2.6.3.2 Therapy Assessment Role In Cancer Management
2.6.3.3 Disease Monitoring Role In Cancer Management
2.6.4 Phases of Adoption - Outlook for Usage
2.6.5 The Promise of Liquid Biopsy
2.7 Industry Structure
2.7.1 Hospital Testing Share
2.7.2 Economies of Scale
2.7.2.1 Hospital vs. Central Lab
2.7.3 Physician Office Lab's
2.7.4 Physician's and POCT
2.8 Profiles of Key Liquid Biopsy Companies
2.8.1 AdnaGen (now Qiagen)
2.8.2 Agena Bioscience
2.8.3 Angle plc
2.8.4 ApoCell
2.8.5 Biocept
2.8.6 BioFluidica
2.8.7 Bio-Rad Laboratories
2.8.8 Boreal Genomics
2.8.10 Chronix Biomedical
2.8.11 Clearbridge BioMedics
2.8.12 Cynvenio
2.8.13 Cytolumina Technologies Corp
2.8.14 CytoTrack
2.8.15 Diagnologix LLC
2.8.16 Epic Sciences
2.8.17 Exosome Diagnostics
2.8.18 Exosome Sciences
2.8.19 Fluidigm Corp
2.8.20 Fluxion Biosciences
2.8.21 Genomic Health
2.8.39 GRAIL
2.8.22 Guardant Health
2.8.23 HansaBiomed
2.8.23 Horizon Discovery
2.8.24 iCellate
2.8.25 Illumina
2.8.26 Inivata
2.8.27 Janssen Diagnostics
2.8.28 Molecular MD
2.8.29 Myriad Genetics
2.8.30 Natera
2.8.31 New Oncology
2.8.32 Personal Genome Diagnostics
2.8.33 RainDance Technologies
2.8.34 Rarecells SAS
2.8.35 Silicon Biosystems
2.8.36 Sysmex Inostics
2.8.37 SRI International
2.8.38 Trovagene
3. Market Trends
3.1 Factors Driving Growth
3.1.1 Non Invasive Game Changer
3.1.2 Lower Cost
3.1.3 Greater Accuracy.
3.1.4 Wide Range of Potential Uses
3.1.5 Aging Population
3.2 Factors Limiting Growth
3.2.1 Lower prices
3.2.2 Lack of Standards.
3.2.3 Protocol Resistance.
3.2.4 Initial Adoption Has No Cost Savings
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role.
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing Fuels a Revolution
3.4.2 Impact of NGS on pricing
3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.4 CGES Testing, A Brave New World
3.4.5 Biochips/Giant magneto resistance based assay
4. Liquid Biopsy Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.2 Illumina Forms GRAIL to Enable Early Cancer Detection via Liquid Biopsy
4.3 ASCO: Researchers Present Advances, Ongoing Challenges in Liquid Biopsy
4.4 Guardant Health, SWOG Partner on Prospective NSCLC Liquid Biopsy Study
4.5 Qiagen Expands CDx Deal with Tokai; Acquires CTC Assets from AdnaGen
4.6 Biodesix's GeneStrat Liquid Biopsy Lung Cancer Test
4.7 Baylor, TGen Collaborate on Personalized Cancer Treatment Options
4.8 Liquid Biopsy Firm Resolution Bio Gets CLIA Certification for Lab
4.9 Broad Institute Lands $10M Gift to Study Cancer Drug Resistance
4.10 Biocept Q1 Revenues Rise With Test Volume Growth
4.11 CRUK Manchester Institute Joins European Consortium Validating Blood-based Cancer Biomarkers
4.12 New Oncology Closes Financing Round to Promote Genetic Testing from Blood
4.13 Cynvenio to present new clinical data
4.14 EKF, Angle Collaborate for Liquid Biopsy Development
4.15 Trovagene Collaborates with UCSD for EGFR Monitoring in Lung Cancer
4.16 AstraZeneca Initiates CDx Partnerships with Roche, Qiagen
4.17 Horizon, LGC Awarded Research Grant for Cancer Diagnostics
4.18 Merck Serono and Sysmex Inostics Announce Testing Center
4.19 Agena Bioscience Launches Smaller Format MassArray
4.20 Personal Genome Diagnostics Aims for FDA Clearance
4.21 HTG Molecular Diagnostics Files for IPO of up to $60M
4.22 Genomic Health Reports 5 Percent Revenue Growth in Third Quarter
4.23 Biocept, Rosetta Genomics Partner to Profile microRNAs from CTCs
4.24 Inivata Raises $6.6M to Develop ctDNA Assays
4.25 Epic Sciences Raises $30M in Private Financing
4.26 New Release in Line of Liquid Biopsy CLIA Tests
4.27 Collaborators Publish Data on Resolution Bio Liquid Biopsy Test
4.27 Trovagene's Urine-Based Liquid Biopsy Platform Demonstrated in Field
4.28 FDA Sends Pathway Genomics Untitled Letter Over Liquid Biopsy Test
4.29 DNA in blood can track cancer development, response in real time
5. Country Market Sizes - North America
6. Country Markets - Europe
7. Country Markets - Asia Pacific
8. Country Markets - Latin America, Africa & The Middle East
9. Global Market Summary
10. Potential Market Opportunity Sizes
Appendices
I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule - National Limit and Midpoint
II. FDA Approved Human Genetic Tests
III. FDA Approved Pharmacogenomics Tests
Companies Mentioned
- AdnaGen (now Qiagen)
- Agena Bioscience
- Angle plc
- ApoCell
- AstraZeneca
- Biocept
- Biodesix
- BioFluidica
- Bio-Rad Laboratories
- Boreal Genomics
- Broad Institute
- Chronix Biomedical
- Clearbridge BioMedics
- CRUK Manchester Institute
- Cynvenio
- Cytolumina Technologies Corp
- CytoTrack
- Diagnologix LLC
- Epic Sciences
- Exosome Diagnostics
- Exosome Sciences
- Fluidigm Corp
- Fluxion Biosciences
- Genomic Health
- GRAIL
- Guardant Health
- HansaBiomed
- Horizon Discovery
- HTG Molecular Diagnostics
- iCellate
- Illumina
- Inivata
- Janssen Diagnostics
- Merck Serono
- Molecular MD
- Myriad Genetics
- Natera
- New Oncology
- Personal Genome Diagnostics
- Qiagen
- RainDance Technologies
- Rarecells SAS
- Silicon Biosystems
- Sysmex Inostics
- SRI International
- Trovagene
For more information visit http://www.researchandmarkets.com/research/4s4ldq/in_vitro_cancer
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.